Summary.-A TLX-5 mouse lymphoma which was resistant to 1-,B-D-arabinofuranosyl cytosine (AraC) was used in vivo to study the possibility of using liposomes as drug-delivery vehicles in order to overcome drug resistance.
In vivo MTX was more effective in the liposomally associated form, whereas liposomally entrapped AraC and AraCTP were ineffective. It is proposed that in vivo liposomally associated drugs may be acting not by actively localizing in the tumour cells, but by the liposomes providing a slow-release drug depot, improving the pharmacokinetic properties of MTX.
A NUMBER OF AUTHORS have previously reported the successful application of liposomally trapped anti-tumour drugs in the treatment of several animal tumours in vivo (Gregoriadis & Neerunjun, 1975; Kimelberg & Achison, 1978; Kobaashi et al., 1977; Kosloski et al., 1978; Mayhew et al., , 1978a . However, there are doubts as to the exact mechanism(s) by which liposomally trapped drugs exert their therapeutic effects. They may act in a number of ways: (a) by accumulating in tumour tissue (Neerunjun et al., 1977) , (b) by acting as a drug storage depot, slowly releasing drug over a longer period (Juliano & Stamp, 1978) , or (c) by reducing toxicity to the normal tissues of the animal (Rahman et al., 1978) . Studies in drug-resistant tumours have proved useful in analysing some of these problems, as well as looking at the possibility of using liposomes to overcome drug resistance (Kaye et al., 1980; Papahadjopoulos & Post, 1976; Richardson et al., 1982) .
Using the same TLX-5 AraC-resistant tumour cell line as used in the in vitro studies outlined in the accompanying paper (Richardson et al., 1982) , we set out to analyse the possibilities of using the AraCTP trapped in liposomes to overcome drug resistance in vivo.
Preparation of liposomes.-Liposomes were prepared from compositions of egg phosphatidyl choline (PC), cholesterol (C), phosphatidic acid (PA) and stearylamine (SA). Most experiments were performed with liposomes composed of a 7:2: 1 molar ratio of PC: C: PA.
One hundred mg of lipids in chloroform were rotary-evaporated to dryness under vacuum at 36°C. To the dry lipid film was added either physiological saline (1 ml) or the drugs AraC, AraCTP or MTX in an identical volume of saline. The lipid was allowed to swell in the aqueous solution, and was agitated to remove all traces of lipid from the sides of the flask. The flask was then surrounded by an ice bath and, using an exponential 2mm diameter titanium probe, was sonicated for 10 bursts of 30 sec with 30 sec cooling between, using a 120W sonicator setting of 6-8 ,um peak-to-peak. This treatment produced liposomes with diameters of the order of 50-100 nm. Liposomes thus prepared were then left for 30 min before G50 filtration to separate from free drugs.
Liposomes and liposomes containing drugs were sterilized by passage through sterile 0 45 ,m millipore filters into sterile ampoules. A small proportion of the drug-containing samples were taken for spectrophotometric (MTX) of free drug. The liposomally trapped MTX also appeared to be therapeutically more active over a slightly wider range of concentrations. Table II compares the effects of liposomally trapped MTX, free MTX and empty liposomes mixed with free MTX on the survival times of tumour-bearing mice, for two doses of MTX.
There appeared to be no difference in results between the free form of the drug and the free drug mixed with empty liposomes at the concentration tested. At the higher dose of MTX the free drug was more active in prolonging survival, whereas at the lower dose the liposomally trapped drug was most effective. Fig. 4 shows the plasma levels of [3H]-MTX after i.p. administration of free or liposomally trapped [3H]-MTX. The free drug was cleared most rapidly from the plasma. The liposomal form of the drug was cleared less rapidly and remained about 10 x the level of the free drug over the 6 h period of measurement.
DISCUSSION
In the accompanying paper (Richardson et al., 1982) we showed that in vitro liposomally trapped AraCTP was able to (Richardson et al., 1982) . The lack of effectiveness of the liposomally trapped AraCTP on the TLX-5 AraC-resistant cell line indicated that the liposomes may not help AraCTP to enter the cells in vivo. Considering the results of the in vitro studies (Richardson et al., 1982) (Sherphof et al., 1978) . Both liposomally trapped and free MTX were effective against the tumour, which indicates a significant difference between this drug and AraC. The tumour cells had no intrinsic resistance to MTX. Therefore if the drug leaked from the liposomes and then entered the tumour cells there would be an observable cytotoxicity. We cannot, therefore, test whether the effects we observed were due to tumour localization of liposomes containing MTX or to the leakage of the drug from the liposomes followed by its entry into the cells. Liposomally trapped MTX was more effective against the tumour than was the free drug. It seems very likely that this is due to liposomes prolonging the exposure of the tumour cells to MTX, by acting as a slow-release storage depot. This is compatible with the observed blood levels of MTX after administration of free and entrapped MTX (Fig. 4) .
Other workers have shown that both AraC and MTX are more effective against tumours when given as a slow infusion (Tattersall, 1977) . It is believed that this is due to changes in the pharmacokinetics of the drugs leading to higher and prolonged levels of the drugs in the bood and tissues. It has also been shown, using AraC and MTX in water-oil-water emulsions, that this presentation served as a slow-release storage depot and prolonged the half-life of the drugs (Benoy et al., 1974) and also increased their effectiveness against tumours at lower dose levels As our studies have shown no activity with entrapped AraCTP but have with MTX, we propose that this slow release was the mechanism by which liposomes were acting in our studies. The blood levels of MTX when the drug was administered in the free and entrapped form suggest this may be the case. Blood levels with the entrapped drug were 5-10 x the levels observed for identical doses of the free drug. This value corresponds to a 5-10-fold lower dose of the liposomal form of the drug to give a similar effect to that with the free drug.
Obviously more biochemical work is required to elucidate fully what is happening when AraCTP is administered in liposomes, but it appears that the use of liposomes will not simply overcome drug resistance to AraC.
It is important, however, that liposomal entrapment did have some effects with methotrexate, and may therefore have some therapeutic advantages in prolonging localized release of anticancer drugs. This may be of great value in the treatment of certain tumours in the lymphatics, a tissue in which liposomes have been found to localize greatly after interstitial injection . 
